MaaT Pharma S.A.: MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris
MaaT Pharma becomes the first company developing microbiome-based drugs to be listed on the regulated market of Euronext Paris Capital increase of €31.5m and which could be increased to €36.2m